Skip to main content

Cellbyte

Category: AI in Healthcare

AI-native platform accelerating pharmaceutical drug launches through automated data analysis and insights Cellbyte was founded in 2024. The company is led by Felix Steinbrenner. Based in Munich, Germany. Team size: 3. Total funding raised: $2.75 million. Latest round: Seed. Key investors include Frontline Ventures, Y Combinator, Pace Ventures, Saras Capital, Springboard Health Angels.

Founded
2024
Headquarters
Munich, Germany
Team size
3
Total funding
$2.75 million

Value proposition

Reduces drug launch timelines by 50% via AI-driven automation, real-time data analysis, and workflow optimization

Products and solutions

AI copilots for P&MA teams, Real-time clinical, pricing, and regulatory data analysis tools, Natural language query interface for complex data insights, Drug Explorer for global regulatory and pricing data, Document Intelligence for multilingual document analysis, Agentic Workflows for automated processes

Unique value

Specialized AI models trained on pharmaceutical domain data, combining clinical, pricing, and regulatory workflows with real-time processing capabilities

Target customer

Pharmaceutical companies (specifically Pricing & Market Access teams) and global drug launch stakeholders

Industries served

Pharmaceuticals, Healthcare technology, Life sciences

Technology advantage

Processes millions of data points in real-time, automating tasks like HTA strategy design, pricing corridors, and payer negotiations

How they differentiate

Cellbyte integrates clinical, pricing, regulatory, and Health Technology Assessment (HTA) data into a unified AI platform, offering real-time insights and automation for drug launch workflows. Unlike competitors, it focuses on continuous market tracking and natural language query capabilities for pricing strategy

Main competitors

Legacy pharmaceutical databases and consulting firms, Traditional market access tools

Key partnerships

Frontline Ventures (lead seed investor), Y Combinator (accelerator), Bayer (pharma client), Springboard Health Angels, Pace Ventures, Saras Capital

Notable customers

Bayer

Major milestones

Secured $2.75M seed funding in November 2025, Onboarded major pharmaceutical clients including Bayer within weeks of launch, Expanded into key global markets (U.S., Europe), Reached six-figure annual recurring revenue (ARR)

Growth metrics

Achieved six-figure ARR within weeks of launch; plans to triple team size post-funding

Market positioning

Positioned as an AI-native platform accelerating pharmaceutical drug launches through automated data synthesis and market intelligence, targeting global pharmaceutical companies seeking to reduce time-to-market

Geographic focus

Primarily focused on major pharmaceutical markets including the U.S., Germany, France, and the U.K., with plans for international expansion

Patents and IP

No public patents mentioned; focus on proprietary AI models and workflows

About Felix Steinbrenner

Second-time founder and Y Combinator alumnus with prior success selling $3M+ ACV enterprise deals to customers like H&M through a previous YC startup. Combines entrepreneurial experience with AI application expertise in healthcare.

Official website: